GlobalData on MSN
Innovent receives NMPA approval for Tabosun colon cancer treatment
Innovent Biologics has received China’s NMPA approval for the NDA for Tabosun, a CTLA-4 monoclonal antibody for colon cancer.
Postoperative cfDNA levels and ctDNA detection rates in patients with stage II colon cancer screened for CIRCULATE (AIO-KRK-0217, ABCSG). Development and validation of machine learning risk prediction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback